Abstract: Aspects of the present invention relate to hinge apparatus (3-n) for supporting an aperture closure member (4). The hinge apparatus (3-1, 3-2) (3-n) is configurable in at least first and second configurations. The hinge apparatus (3-1, 3-2) (3-n) includes a first hinge bracket (10) (10) and a second hinge bracket (11) (11). A first hinge linkage member (15) is pivotally mounted to each of the first and second hinge brackets (10, 11) (10, 11). A second hinge linkage member (16) (16) is pivotally mounted to each of the first and second hinge brackets (10, 11) (10, 11). A latching mechanism (25) (25) is provided for selectively latching the hinge apparatus (3-1, 3-2) (3-n). The latching mechanism (25) (25) is operable to inhibit movement of the first and second hinge linkage members (15, 16) (15, 16) relative to each other to latch the hinge apparatus (3-1, 3-2) (3-n).

Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.

Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity.

Abstract: Capacitive touch sensors are integrated with a head-mounted display (HMD) device or other video eyewear devices to create a more reliable and more intuitive user interface. The sensors, which may be implemented as an array, control various aspects of a left and right channel multimedia presentation, such as interpupillary distance or stereoscopic convergence, brightness, volume, or power mode.

Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.

Abstract: A method of inhibiting activity of a cathepsin L-like protease in cells or tissue and the use of the method in the treatment of disease such as cancer and inflammatory diseases is described. The method comprises administration of a cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide. In particular embodiments, the propeptide is a Cathepsin S propeptide. Further, the use of propeptides having an Fc portion is described.

Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.

Abstract: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.

Abstract: Described is a method of producing a soluble bioactive domain of a protein, the method comprising the step of selecting suitable soluble subunits of a protein and assessing the produced protein for desired activity. The method may comprise the steps of amplifying DNA encoding at least one candidate soluble domain, cloning the amplified DNA into at least one expression vector, using each of said vectors into which the DNA has been cloned to each transfect or transform one or more host cell strains, expressing said DNA in one or more host cell strains, and analyzing expression products from said host cells for solubility.